Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2
J. Zou, C. Kurhade, et al.
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Human antibodies to SARS-CoV-2 with a recurring YYDRXG motif retain binding and neutralization to variants of concern including Omicron
H. Liu, C. I. Kaku, et al.
Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants
J. Logue, R. M. Johnson, et al.
Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters
R. R. G. Machado, J. L. Walker, et al.
A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration
H. Ma, X. Zhang, et al.
